A dozen lawyers will lead a growing number of lawsuits brought over Tepezza, an infusion drug that treats thyroid eye disease.
More than 40 lawsuits allege that Tepezza, which the U.S. Food and Drug Administration approved in 2020, causes permanent hearing loss or ringing in the ears and that manufacturer Horizon Therapeutics USA Inc. failed to warn patients of these problems.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
